Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

129 results about "Thiogalactosides" patented technology

Recombinant antigen protein for diagnosing echinococcosis granulosa as well as preparation method and application thereof

The invention discloses a recombinant antigen protein (of which the amino acid sequence is shown as SEQ ID NO:1) for diagnosing echinococcosis granulose. Moreover, the invention further discloses a preparation method of the recombinant antigen protein. The method comprises the following steps of: amplifying an EgENO gene by adopting RT-PCR (Reverse Transcription-Polymerase Chain Reaction); cloning the EgENO gene into an expression vector PET28a (+) for constructing a recombined plasmid PET28a-EgENO; converting into escherichia coli BL21(DE3); inducing the expression of a recombinant protein through IPTG (Isopropyl-beta-d-Thiogalactoside); and identifying a purified recombinant antigen by using SDS-PAGE (Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis) and Western blotting. In addition, the invention further discloses a diagnosis application of the recombinant antigen protein. As proved by an experiment, the recombinant antigen protein has the advantages of high sensitivity, high specificity and the like for the diagnosis of the echinococcosis granulosa, and has a wide application prospect on the aspect of diagnosis of the echinococcosis granulosa.
Owner:STATION OF VIRUS PREVENTION & CONTROL CHINA DISEASES PREVENTION & CONTROL CENT

Citrus fruit fly odorant binding protein-based attractant screening method

The invention discloses a citrus fruit fly odorant binding protein-based attractant screening method belonging to the technical field of bioengineering. The citrus fruit fly odorant binding protein-based attractant screening method comprises the following steps of: collecting the total RNA (Ribonucleic Acid) of antennae of a citrus fruit fly; obtaining the overall length of a citrus fruit fly odorant binding protein through RT-PCR (Reverse Transcription-Polymerase Chain Reaction); constructing a prokaryotic expression vector of the citrus fruit fly odorant binding protein; inducing the expression of a citrus fruit fly recombinant odorant binding protein through IPTG (isopropyl-beta-d-thiogalactoside), and purifying the citrus fruit fly recombinant odorant binding protein through a nickel sepharose gel affinity column; obtaining a conjugation reaction spectrum of the citrus fruit fly recombinant odorant binding protein and a host fruit odor volatile matter through a competitive fluorescence combing method, wherein a dissociation constant (KD) is lower than below 10 mu mol/L host fruit smell; and the IC 50 value of fluorescence competition is less than 30 mu mol/L, determining a host fruit smell attractant suitable for the citrus fruit fly. The invention provides a new strategy for screening and designing a citrus fruit fly odorant host fruit smell odor information attractant formula.
Owner:CHINA JILIANG UNIV

Genetic engineering bacterial strain for expressing bacillus subtilis laccase in strain cell and method for realizing secreting and expressing laccase in bacterial strain

The invention discloses a genetic engineering bacterial strain for expressing bacillus subtilis laccase in a strain cell and a method for realizing secreting and expressing laccase in a bacterial strain, and relates to the genetic engineering bacteria strain for expressing bacillus the subtilis laccase in the strain cell and the method for realizing secreting and expressing laccase in the bacterial strain. A preparation method for the genetic engineering bacterial strain comprises the following steps: I, extracting DNA of a bacillus genome and cloning a bacterial laccase gene; and II, constructing a recombinant expression bacterial strain. An inducing method for realizing secreting and expressing recombinant laccase comprises the following steps: I, accessing the engineering bacterial strain into an LB (liquid-phase basicity) culture medium to culture until OD600 is 0.8; and II, adding 0.1 mM of IPTG (isopropyl-beta-d-thiogalactoside) and 0.1 mM of CuSO4 to culture for 4 hours at 25 DEG C under 120 rpm, and then performing static culture at 30 DEG C. The inducing method provided by the invention can remarkably improve the secretion effects of the recombinant laccase, is simple to operate, and has a high reference value in improving recombinant escherichia coli to secrete laccase.
Owner:NORTHEAST FORESTRY UNIVERSITY

I-group 4-type aviadenovirus genetic engineering subunit vaccine and preparation method thereof

The invention provides an I-group 4-type aviadenovirus genetic engineering subunit vaccine and a preparation method thereof. According to the technical scheme, the preparation method comprises the following steps: cloning an encoding gene of fibrous protein C-terminal from an I-group 4-type aviadenovirus genome according to a PCR technology and performing sequence analysis; cloning the gene to an expression vector pET-32a, transforming escherichia coli, constructing engineering bacteria, and inducing the engineering bacteria by isopropyl-beta-D-thiogalactopyranoside to express the fibrous protein C-terminal; performing lysis on an engineering bacterial cell, performing centrifugal separation on an inclusion body of the engineering bacterial cell, dissolving urea and diluting for renaturation; preparing the vaccine according to the conventional preparation method of a mineral oil adjuvant inactivated vaccine. According to the I-group 4-type aviadenovirus genetic engineering subunit vaccine prepared by the method, the immune effect of the vaccine is evaluated by a serological method and an immunity challenge method, and the result indicates that the aviadenovirus inactivated vaccine prepared by the method can provide effective immunoprotection and has a good commercialized development prospect.
Owner:TIANJIN RINGPU BIO TECH

Simple and efficient method for preparing and purifying TaqDNA polymerase

The invention provides a simple and efficient method for preparing and purifying TaqDNA polymerase. The method includes: 1) establishing a TaqDNA polymerase expression vector pET-30aTAQ; 2)converting the TaqDNA polymerase expression vector pET-30aTAQ on a kanamycin low salt LB plate, obtaining a bacterial strain BL21 (DE3) / pEP-30aTAQ; 3) inoculating in a kanamycin low salt LB fluid nutrient medium, and performing shake cultivation until OD600=0.4-0.9; 4) performing isopropyl-beta-d-thiogalactoside (IPTG) induction for 2-24 hours; 5) collecting supernatant of the medium in centrifugal mode; 6) heating the supernatant for 10 minutes at the temperature of 80-100 DEG C, and performing ice-bath for 1 minute at the temperature from 0 DEG C to -20 DEG C; 7) collecting supernatant in centrifugal mode; and 8) freezing enzyme liquid after detection so as to obtain finished enzyme. The simple and efficient method has the advantage that purification is finished through two-step centrifugation and one-step thermal circulation, and the method is simple. The simple and efficient method for preparing and purifying the TaqDNA polymerase omits a bacteria cracking process and subsequent multifarious purification steps of a traditional method, improves purification of the TaqDNA polymerase, reduces pollution, saves preparation cost, shortens production cycle, and can be applied to continuous online immobilized production of the TaqDNA polymerase.
Owner:HUBEI UNIV

Recombineering-mediated gene knockout method of corynebacterium glutamicum ATCC 13032

The invention relates to a recombineering-mediated gene knockout method of corynebacterium glutamicum ATCC 13032. The gene knockout method comprises the following specific implementation steps: obtaining a DNA fragment which is provided with 500-bp homologous sequences on two sides aiming at genes to be knocked out and a kanamycin resistance gene in the middle through a polymerase chain reaction amplification; carrying out electrotransformation on the DNA fragment into a corynebacterium glutamicum ATCC 13032 cell in which recombinase is induced to express by isopropyl-Beta-D-thiogalactopyranoside, and enabling the kanamycin resistance gene to replace the target gene through the resistance selection of kanamycin to obtain gene knockout strains; finally, cultivating mutant strains in a solid medium containing cane sugar to eliminate plasmids containing recombinase genes. The gene knockout method adopts simple PCR (Polymerase Chain Reaction) and electrotransformation supplemented by the resistance selection of kanamycin, is free of operating steps, such as gene cloning in molecular biology and other certain operating steps, and simple and rapid, and has important application in the aspects of researching gene functions and producing amino acid.
Owner:NANJING NORMAL UNIVERSITY

Recombinant human TSG-6 protein, preparation method thereof and application of recombinant human TSG-6 protein in treatment of acute inflammatory diseases

The invention discloses recombinant human TSG-6 protein, a preparation method thereof and application of the recombinant human TSG-6 protein in the treatment of acute inflammatory diseases. The aminoacid sequence of the recombinant human TSG-6 protein is as shown in SEQ ID No. 1, and the encoding gene nucleotide sequence of the recombinant human TSG-6 protein is as shown in SEQ ID No. 2. The recombinant human TSG-6 protein and the preparation method and application thereof have the advantages that a prokaryotic expression vector pET30a is utilized to build an Escherichia coli BL21(DE3) host strain capable of expressing the recombinant human TSG-6 protein, the strain is subjected to multiplication culture, isopropyl-beta-D-isopropylthiogalactoside induced expression and centrifuging are performed to obtain a thallus, the thallus is split and then inclusion body precipitate is collected centrifugally, and denaturation, renaturation and molecular-sieve purification are performed to obtain the recombinant human TSG-6 protein; the recombinant human TSG-6 protein has a good curative effect on the acute pneumonia, caused by HCMV virus infection, of mice and provides a new thought for thetreatment of the acute inflammatory diseases caused by virus infection.
Owner:ANHUI MEDICAL UNIV

Fusion protein with clostridium difficile toxins A/B and encoding gene and application of fusion protein

The invention provides a fusion protein with clostridium difficile toxins A/B and an encoding gene and application of the fusion protein. The sequence of the fusion protein with the clostridium difficile toxins A/B is represented by SEQ ID NO:2, and the encoding gene is represented by SEQ ID NO:1. According to the fusion protein, a carrier fragment consisting of a clostridium difficile toxin A carboxyl terminal gene and a prokaryotic expression vector pET32b(+) which are modified through a codon and a fusion gene fragment consisting of a clostridium difficile toxin B carboxyl terminal structure and a flexible chain are obtained through PCR (polymerase chain reaction) multiplication segmentation; the obtained fusion fragment and the obtained carrier are respectively connected in an enzyme recycling manner, so that a recombined expression plasmid pET32b(+)-ToxA-ToxB can be obtained; after the recombined plasmid converts a host BL21(DE3) strain, the recombined plasmid can be subjected to induction expression by IPTG (isopropyl-beta-d-thiogalactoside) to obtain the fusion protein with the clostridium difficile toxins A/B. According to the fusion protein with the clostridium difficile toxins A/B, the fusion protein with the immunogenicity of the toxins A and B can be obtained, and the difficulty and the cost for researching and producing a CDAD (clostridium difficile associated diarrhea) vaccine can be reduced.
Owner:冯东晓

Method for preparing virus analogs of nervous necrosis viruses

The invention belongs to the technical field of biology, and relates to a method for preparing virus analogs of nervous necrosis viruses. The method comprises the following steps of: (1) performing expression of the virus analogs of the nervous necrosis viruses on escherichia coli of pQE30 plasmid vectors coded with nervous necrosis virus capsid protein genes under the pronucleus condition, wherein the expression is performed under the following conditions of: inoculating 1 mass percent of escherichia coli solution of which OD600 is equal to 1.5 into a culture medium, culturing the escherichia coli at 37 DEG C under 250rpm till the OD600 is 0.3 to 0.5, adding isopropyl-beta-D-thiogalactoside into the escherichia coli solution till the final concentration of the isopropyl-beta-D-thiogalactoside is 900muM, transferring the solution, and continuously culturing the escherichia coli for 3 to 4 hours at the temperature of between 25 and 30 DEG C at the rotational speed of 200rpm to finish the expression; and (2) after the expression is finished, breaking, separating and purifying the strains to obtain the virus analogs of the nervous necrosis viruses, wherein the plasmid coded genes also can be nervous necrosis virus capsid protein genes containing histidine tags, and the expression product of the genes can be purified by affinity chromatography. The method provided by the invention can obtain high virus analog expression amount; and the chromatography and purification method is simple and convenient and has low costs in required apparatuses and reagents.
Owner:SUN YAT SEN UNIV

Method for producing lactulose through whole-cell catalysis

The invention discloses a method for producing lactulose through whole-cell catalysis, and belongs to the field of the food biotechnology. According to the method, recombinant escherichia coli E. coli BL 21 (DE3) for producing cellobiose epimerase is taken as production bacterial strains, lactose is used for replacing isopropyl-beta-D-sulfo-galactoside (IPTG) and taken as an inductive agent for fermental cultivation, and thalluses obtained through centrifugation are subjected to ethyl alcohol permeabilization and vacuum freeze drying to serve as a cell biocatalyst for directly converting the lactose to produce the lactulose. The maximum percent conversion of the lactulose can reach 65.1%, the concentration of the lactulose reaches 390.6 g/L, the production rate of the lactulose reaches 195.3 g/(L*h), and the production quantity of by-product epidepride lactulose is smaller than 2%(w/w). According to the method, microbial cells are directly used for converting the lactose to produce the lactulose, and the method is simple and easy to implement, avoids the loss of enzyme activity in the separation and purification process, greatly reduces the cost of producing the lactulose through an enzymic method and is beneficial for achieving industrialization of lactulose production through the enzymic method early.
Owner:JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products